The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Genomics in pharma: anti-sense oligonucleotidesBuy the report here.

Smarter leaders trust GlobalData


Premium Insights Genomics in pharma: anti-sense oligonucleotides

Buy the Report

Premium Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s Technology Foresights, which uses over 668,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.

Anti-sense oligonucleotides is a key innovation area in genomics

Anti-sense oligonucleotides are synthetic, single-stranded strands of DNA or RNA sequences that can bind to complementary target RNA sequences, leading to the degradation or inhibition of translation of the target RNA. By targeting specific RNA sequences, anti-sense oligonucleotides can modulate gene expression and have potential therapeutic applications in treating various diseases.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies.  According to GlobalData, there are 150+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of anti-sense oligonucleotides.

Key players in anti-sense oligonucleotides – a disruptive innovation in the pharmaceutical industry

‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.   

‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.  

Patent volumes related to anti-sense oligonucleotides

Company Total patents (2010 - 2022) Premium intelligence on the world's largest companies
Ionis Pharmaceuticals 1343 Unlock Company Profile
F. Hoffmann-La Roche 343 Unlock Company Profile
Alnylam Pharmaceuticals 286 Unlock Company Profile
Nippon Shinyaku 183 Unlock Company Profile
Sanofi 143 Unlock Company Profile
Novo Nordisk Foundation 129 Unlock Company Profile
Sarepta Therapeutics 125 Unlock Company Profile
Regulus Therapeutics 120 Unlock Company Profile
Wave Life Sciences 93 Unlock Company Profile
Biogen 93 Unlock Company Profile
ProQR Therapeutics 90 Unlock Company Profile
Nogra Two 90 Unlock Company Profile
Cold Spring Harbor Laboratory 87 Unlock Company Profile
Centre National de la Recherche Scientifique 81 Unlock Company Profile
Avidity Biosciences 76 Unlock Company Profile
Arbutus Biopharma 65 Unlock Company Profile
Bio-Path 61 Unlock Company Profile
Daiichi Sankyo 56 Unlock Company Profile
Replicor 54 Unlock Company Profile
Novartis 52 Unlock Company Profile
National Center of Neurology and Psychiatry 52 Unlock Company Profile
Pfizer 49 Unlock Company Profile
Neurovision Pharma 46 Unlock Company Profile
OPKO Health 39 Unlock Company Profile
Biorchestra 39 Unlock Company Profile
Mitsubishi Chemical Group 38 Unlock Company Profile
Bristol-Myers Squibb 37 Unlock Company Profile
Arrowhead Pharmaceuticals 35 Unlock Company Profile
Johnson & Johnson 34 Unlock Company Profile
Scholar Rock 32 Unlock Company Profile
Biomarin Technologies 31 Unlock Company Profile
Merck 30 Unlock Company Profile
Bonac 25 Unlock Company Profile
Triplet Therapeutics 23 Unlock Company Profile
Dynavax Technologies 22 Unlock Company Profile
Stoke Therapeutics 22 Unlock Company Profile
Silence Therapeutics 22 Unlock Company Profile
Intellia Therapeutics 21 Unlock Company Profile
General Hospital 21 Unlock Company Profile
Codiak BioSciences 19 Unlock Company Profile
EdiGene 18 Unlock Company Profile
AptaBio Therapeutics 18 Unlock Company Profile
Erasmus MC 18 Unlock Company Profile
Samjin Pharm 18 Unlock Company Profile
Viridian Therapeutics 17 Unlock Company Profile
Aligos Therapeutics 17 Unlock Company Profile
Kirin 17 Unlock Company Profile
Massachusetts General Hospital 17 Unlock Company Profile
Antisense Therapeutics 16 Unlock Company Profile
Centre Leon Berard 16 Unlock Company Profile

Source: GlobalData Patent Analytics

Ionis Pharmaceuticals (Ionis) is one of the leading patent filers in anti-sense oligonucleotides. Formerly known as ISIS Pharmaceuticals, Ionis focuses on the discovery and development of RNA-targeted drugs. The company develops medicines to treat various diseases including cancer, pulmonary, cardiovascular, neurological and infectious diseases. Its major products include Spinraza for spinal muscular atrophy, Tegsedi for neuropathy and Waylivra for familial chylomicronemia syndrome. Ionis also has a pipeline of products in different phases of clinical development. It develops products based on its proprietary antisense technology. The company partners with other pharmaceutical companies to develop a range of products in different therapeutic areas. F. Hoffmann-La Roche and Alnylam Pharmaceuticals are some of the other key patent filers in anti-sense oligonucleotides.

In terms of application diversity, NeuroVision Pharma leads the pack, while Replicor and Silence Therapeutics stood in the second and third positions, respectively. By means of geographic reach, the NeuroVision Pharma held the top positionm followed by Arbutus Biopharma and Scholar Rock.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Genomics.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.